Novo Nordisk acquires Akero Therapeutics for $5.2 billion, enhancing its MASH treatment pipeline.
Author: PharmaSignal News Desk
Colorado Enbrel payment limit set at $600 per unit, impacting Amgen’s pricing strategy and potentially influencing other states.
Domestic Generic Drug Fast-Track Review Program aims to expedite approval for drugs made from domestic materials.
Amgen Repatha pricing sees a 60% reduction in the U.S. through a new program, enhancing market access.
Generic mifepristone approval by FDA expands access to abortion care, offering a new option for patients.
EU pharmaceutical policy overhaul aims to improve access to medicines, impacting millions across Europe.
Chiesi Arbor partnership focuses on advancing gene editing therapies for rare diseases, targeting primary hyperoxaluria type 1.
Pharma companies are seeking agreements with Trump following Pfizer’s deal, aiming to lower drug prices.
Algen AstraZeneca partnership aims to enhance AI-driven drug discovery, focusing on chronic inflammatory conditions for innovative solutions.
Galapagos cell therapy sale decision expected soon as company reviews limited proposals from financial investors.